

AD_____

Award Number: DAMD17-02-1-0356

TITLE: Chromatin Structure and Breast Cancer Radiosensitivity

PRINCIPAL INVESTIGATOR: Tej K. Pandita, Ph.D.

CONTRACTING ORGANIZATION: Washington University
Saint Louis, Missouri 63110

REPORT DATE: October 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050630 074

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2004		3. REPORT TYPE AND DATES COVERED Annual (15 Sep 2003 - 14 Sep 2004)
4. TITLE AND SUBTITLE Chromatin Structure and Breast Cancer Radiosensitivity			5. FUNDING NUMBERS DAMD17-02-1-0356	
6. AUTHOR(S) Tej K. Pandita, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University Saint Louis, Missouri 63110 E-Mail: pandita@radonc.wustl.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The hMOF protein is a chromatin-modifying factor. Chromatin structure plays a critical role in gene expression. Since hMOF has a chromodomain region as well as acetyl transferase activity, its inactivation can influence modification of chromatin during DNA metabolism. The proposed experiments of this grant proposal will determine functions of hMOF gene. This will be achieved by generating isogenic cells with and without hMOF function. Both <i>in vivo</i> and <i>in vitro</i> experiments will be performed to determine the function of hMOF in context with radioresponsiveness and oncogenic transformation. If hMOF proves to be involved in the radioresponsiveness and neoplastic transformation, then the clinical implications of this proposal are highly significant. It may, in the future, be prudent to screen each breast cancer patient prior to any final therapeutic decision. This will be accomplished through the use of quantitative RTPCR and the test results can be obtained within a day. There are several benefits of identifying an individual's normal tissue with loss of hMOF gene expression. First, it will allow us to prospectively identify the sensitive subset of patients. Second, the radiosensitive patients will be taken for an alternative therapy if exist and would be spared a great deal of suffering. Third, it will be possible that once we identify a subset of patients that show a genetic basis of radiation sensitivity, the radiation dose to the remaining breast patients could be increased to be more effective for local tumor control. Fourth, it will provide health professionals a molecular diagnostic approach to predict the suitability of an individual for radiotherapy.				
14. SUBJECT TERMS Breast, chromatin, DBA			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	Page 1
SF 298.....	Page 2
Table of Contents.....	Page 3
Introduction.....	Page 4
Body.....	Page 4
Key Research Accomplishments.....	Page 6
Reportable Outcomes.....	Page 6
Conclusions.....	Page 6
References.....	Page 7
Appendices.....	Page 7

Introduction:

Most patients with breast cancer tolerate radiotherapy well with only limited acute, reversible adverse effects. However, about 5% of patients experience severe, delayed complications such as skin pigmentation changes, subcutaneous fibrosis, rib fractures, cardiac disease, pulmonary fibrosis, second primary cancer (specifically esophageal squamous-cell carcinoma as well as adenocarcinoma) and other complications, which manifest several years after treatment with ionizing radiation. Epidemiological studies have shown that irradiation of the breast especially among young women, increases the risk for subsequently developing breast cancer. It might thus be expected that genes that are known to influence radiation sensitivity may be associated with the radiotherapy related adverse effects. The human genes that have been found to be responsible for ionizing radiation sensitivity are *ATM* (ataxia telangiectasia mutated), *BRCA1*, *BRCA2*, *NBS1*, etc. Mutations in *BRCA1* and *BRCA2* contribute to about 15% of familial breast cancer risk and their contribution to sporadic breast cancer is very low. In such cases, genes frequently altered in the general population, e.g., *ATM* may be an important risk factor. However, screening for *ATM* mutations in sporadic breast cancer cases has not revealed the magnitude of involvement of the *ATM* gene expected. Since *ATM* as well as *BRCA1* have been reported to interact with chromatin modifying factors, it is possible that such factors may be involved in the radiation-induced morbidity. Therefore, there is a need for the identification of chromatin modifying factors involved in ionizing radiation sensitivity, genomic instability and carcinogenesis.

Body

Specific Aims:

The goal of this proposal is to understand the mechanisms underlying radiosensitivity. Two specific questions are being addressed in this grant application: (1) Whether hMOF is involved in ionizing radiation (IR) response and; (2) Whether hMOF is involved in pathobiology of the breast cancer. We proposed to complete the following aims: (1) To determine whether mutations in the *hMOF* gene correlate with ionizing radiation sensitivity. (2) To generate MOF knockout mice in order to determine the pathobiology of gene. (3) To determine whether ionizing radiation enhances neoplastic transformations in mouse embryonic fibroblasts of MOF knockout mice. MOF knockout mice will also be examined for spontaneous as well as IR-induced tumor formation.

Studies and Results during second year of funding:

During the second year, we have addressed the specific aim 2. This specific aim allowed us to determine the interaction of hMOF with ATM and generate mouse MOF targeting vector for generating mouse knock out mice.

Task2. (a) To generate MOF knockout mice in order to determine the pathobiology of gene:

To assess the contribution of hMOF in mammalian development, we first determined the expression status of hMOF using a multi-tissue Northern blot analysis. Expression of hMOF mRNA was found in all tissues (Fig. 1). To understand the genopathology of hMOF, we have cloned and sequenced a full-length mouse *Mof* cDNA. To isolate an isogenic *Mof* mouse gene for construction of the targeting vector,




Fig. 1. *hMOF* expression levels: Autoradiograph showing Northern blots from normal human multiple tissues.

Fig. 2. The *mMOF* gene was localized by FISH analysis to distal chromosome 7 (arrow) by the FISH procedure.

Fig. 3. Organization of the wild-type gene, the targeting construct, and the structure of the locus gene targeting. *Bgl*II (B), *Eco*RI (E), *Xba*I (X), *Sal*I (S).

Fig. 4. Southern analysis of tail DNA digested with *Bgl*II and hybridized with a probe located outside the targeting construct (indicated in Fig. 3).

Fig. 5. Gross morphology of embryos. Two normal (left and right) and three mutant embryos dissected at E7.5 (arrow).




Fig. 2

we screened a genomic λ phagelibrary from the mouse strain 129/Sv (Stratagene) using *Mof* cDNA as a probe and obtained three overlapping positive clones containing exons 1-4 of the *Mof*




Fig. 3




Fig. 4

Fig. 5

gene. We identified 4 and 9 kb *Eco*RI fragments of *Mof*. The genomic mouse *MOF* which is localized on chromosome 7 (Fig. 2) A gene-targeting vector was designed to inactivate *mMof* gene after homologous recombination (Fig. 3, 4). Mating between *mMOF* heterozygotes yielded the frequency of wild type (WT), heterozygous (*mMof*+/−) and homozygotes

(mMof+/-) offspring in the ratio of 1:2:0 indicating that mMof is required for normal mouse development. mMof+/- mice were embryonic lethal at day 6.5 (Fig. 5).

(b) Involvement of hMOF in ATM function:

We have determined that hMOF is associated with the ATM (ataxia-telangiectasia mutated) protein. Cellular exposure to ionizing radiation (IR) enhances hMOF-dependent acetylation of its target substrate, lysine 16 (K16) of histone H4, independent of ATM function. Blocking the IR-induced increase in acetylation of histone H4 at K16, either by expression of a dominant negative mutant hMOF or by RNAi-mediated hMOF knockdown, resulted in decreased ATM autophosphorylation, ATM kinase activity, phosphorylation of downstream effectors of ATM and DNA repair while increasing cell killing. In addition, decreased hMOF activity was associated with defective telomere metabolism and loss of the cell cycle checkpoint response to DNA double strand breaks (DSBs). Over-expression of wild-type hMOF yielded the opposite results; increased cell survival and enhanced DNA repair after IR exposure. These results suggest that hMOF influences the function of ATM.

➤ **Key Research Accomplishments**

- We cloned cDNA and genomic mouse MOF gene.
- We made targeting vector to generate the Mof knockout mice.
- We generated mice heterozygous for MOF gene.
- We established the interaction between hMOF and ATM protein.
- We determined hMOF inactivation abrogates ATM functions

c. Reportable Outcomes

1. Cloned cDNA and genomic DNA of mouse MOF gene.
2. Generated mouse MOF heterozygote mice.
3. MOF inactivation results in embryonic lethality.
4. Determined the influences of hMOF on ATM function.

d. Conclusions: Plans for next year (2004-2005):

During the third year, we will complete the work proposed under task 3.

Task 3: (a) The global ablation of Mof function in the mouse resulted in early embryonic lethality, we will construct a targeting vector for conditional mutagenesis, which will allow the global and the tissue-specific inactivation of *Mof*. Currently the *cre/loxP* strategy is probably the most applied system of conditional mutagenesis. Recent advances with the conceptually related *Flpe/FRT* system offers an alternative, and the two systems can be combined advantageously. The *cre/loxP* system requires the generation of two strains of mice. In one of them, the *Mof* sequence to be deleted upon recombination will be flanked by *loxP* sites (*Mof^{lox}*) introduced by homologous recombination in embryonic stem cells. The second mouse strain carries the *loxP* site-specific *cre* recombinase under control of a temporal- or tissue-specific promoter of choice.

(b) To determine whether ionizing radiation enhances neoplastic transformations in mouse embryonic fibroblasts of MOF heterozygous mice.

e. Publications:

We have achieved about 70% of envisaged goals for the second year of this grant. During the current funding period 12 papers were published and 3 are submitted for publication. Each paper contributed to the over all goals of the proposal.

1. **Pandita T.K.** A multifaceted role for ATM in genome maintenance. *Expert Reviews in Molecular Medicine*. 5: 1-21 (2003).
2. **Pandita T.K.** and Roti Roti J.L. Role of Telomerase in Radiocurability. *Oncology Reports*. 10:263-270 (2003).
3. Sharma G.G, Gupta A., Scherthan H., Dhar S., Wang H., Gandhi V., Iliakis G., Young C.S.H., and **Pandita T.K.** hTERT associating with telomeres reduces spontaneous chromosome damage and enhances DNA repair. *Oncogene* 22:130-146 (2003).
4. Sarkar D, Leszczyniecka M, Kang DC, Lebedeva IV, Valerie K, Dhar S, **Pandita TK**, Fisher PB. Related Articles, Links Abstract Downregulation of Myc as a potential target for growth arrest induced by human polynucleotide phosphorylase (hPNPaseold-35) in human melanoma cells. *J Biol Chem*. 278:24542-24551 (2003).
5. Sharma G.G., Hall E.J., Dhar S., Gupta A, Rao P.H. and **Pandita T.K.** Telomere stability correlates with longevity of human beings exposed to ionizing radiations. *Oncology Reports* 10: 1733-1736 (2003).
6. Sharma GG, Hwang K-K., Pandita RK, Gupta A, Dhar S, Prenteau M, Agarwal M, Worman HJ, Wellinger RJ, and **Pandita TK** (2003). Human heterochromatin protein 1 isoforms HP1 and HP1 interfere with hTERT-telomere interactions and correlates with changes in cell growth and response to ionizing radiation. *Mol Cell Biol* 23: 8363-8376.
7. **Pandita TK** (2004) Enrichment of cells in different phases of cell cycle by centrifugal elutriation. *Methods in Molecular Biology*. 241: 17-21.
8. **Pandita TK** (2004) Detecting influence of cell cycle regulatory proteins on human telomeres. *Methods in Molecular Biology*. 241: 329-339.
9. Hunt CR, Dix DJ, Sharma GG, Pandita RK, Gupta A, Funk M, and **Pandita TK** (2004) Genomic instability and enhanced radiosensitivity in Hsp70.1/3-deficient mice. *Mol Cell Biol* 24:899-911.
10. **Pandita TK**, Higashikubo R and Hunt CR. (2004) HSP70 and Genomic Stability. *Cell Cycle*. 3:591-592.
11. Richardson C, Horikoshi N and **Pandita TK** (2004) DNA double-strand break response network in meiosis. *DNA Repair* 3:1149-1164.
12. Shahrabani-Gargir L, **Pandita TK** and Werner H (2004) Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. *Endocrinology* 145:5679-5687.

f. Project-Generated Resources:

Research supported by this grant resulted in generation of mouse heterozygous for MOF.

Appendix: None